Welcome to Bratislava                         4 - 5
Scientific, organizing committee                        6 - 7
Sponsors                        8 - 9
Opening ceremony  10 – 11
Keynote speakers  12 – 15
Time Schedule  16 – 18
Convention centre  19 – 21
Program 22 June 2016  24 – 25
Program 23 June 2016  28 – 42
Program 24 June 2016  46 – 59
Social program  60
General information  61 – 63
City map  64
Posters  66 – 79
Index / Register  80 – 84
Notes / Advertising  86 – 99
Dear colleagues,

On behalf of the Europe Region of the International Union against Tuberculosis and Lung Disease (The Union) I warmly welcome you to the 7th Conference of the Union Europe Region in Bratislava, Slovakia, 22-24 June 2016.

I am pleased to announce that this year’s conference Patron is the President of the Slovak Republic, Mr. Andrej Kiska.

The conference theme is: Know – Share – Act in the Fight against TB and Lung Diseases. This theme reflects the changing field of activity of global public health, and the new era of action within the framework of the Sustainable Development Goals that we will embark on together in the coming years:

- TB poses an intolerable burden of ill health across the countries of Europe with nearly 330,000 women, men and children falling ill every year as a result of the disease and 36,000 of them dying of it.
- Drug-resistant TB is a major challenge in the region. The European Region has the highest percentage of drug-resistant TB in the world and treatment success rates are the lowest.
- Over the next 35 years, 2.1 million people could die from drug-resistant TB in Europe at a total economic cost of USD $1.1 trillion. The investment required to eliminate TB in Europe is a fraction of the potential costs. Inaction is not an option.
- There is an urgent need to scale up investment in TB research and development of new tools and approaches to fight TB and MDR-TB.

The Conference will be held at a particularly significant – and challenging – time, as the Millennium Development Goals era ends and a new development agenda takes hold, guided by the Sustainable Development Goals. The World Health Organization’s new “End TB partnership Europe” will introduce a new mind-shift concept.

The conference will feature 28 symposia and 3 workshops led by world experts, dedicated to the broad issue of TB as a serious infectious disease with a major impact on public health and the fight to combat tobacco use and lung diseases such as chronic obstructive pulmonary disease, pulmonary fibrosis and sleep disordered breathing.

On 22 June 2016 at 5pm the Opening ceremony will be attended by Dr. E. Jane Carter, President of The Union and Dr. Zsuzsanna Jakab, World Health Organization Regional Director for Europe. The opening lecture of the conference will be given by Dr. Mario Raviglione, Director of the Global TB Programme of the World Health Organization who will be presenting the new strategy to fight tuberculosis with the aim of ending TB as an epidemic by 2030/35.

Taking place at the same time as the European Conference is the Slovak National Pneumological Conference “Management of exacerbations of respiratory diseases”.

Delegates – and the public – are also invited to join our inaugural event “Run for healthy lungs” - an evening charitable run on of 22 June 2016 at 20.30h. The aim of this event is to highlight the serious social and medical problems still posed by TB and lung diseases today. Profits will support the Children’s Tuberculosis Institute in Dolný Smokovec.

Plenary sessions, symposia, oral presentations, poster sessions, and workshops will provide a wide range of forums for attendees to hear about new developments, present their work, to meet with colleagues and to explore new partnerships.

I look forward to welcoming you to Bratislava.

Ivan Solovic, President, The Union Europe Region
Patronage over the conference in 2016 – the President of the Slovak Republic His Excellency Andrej Kiska

CONFERENCE PRESIDENTS
• Ivan Solovic, President of the Union – Europe Region, Slovakia
• Marta Hajkova, main specialist of the MoH for TB and Lung Diseases, Slovakia

SCIENTIFIC COMMITTEE 1. INTERNATIONAL
• Ivan Solovic, The Union, Slovakia
• Zohar Mor, The Union, Israel
• Raquel Duarte, The Union, Portugal
• Peter Davies, The Union, UK
• Malgorzata Grzemska, WHO HQ
• Masoud Dara, WHO Europe

SCIENTIFIC COMMITTEE 2. NATIONAL
• Marta Hajkova, Slovakia
• Jozef Jarab, Slovakia
• Peter Krystufek, Slovakia
• Ivan Majer, Slovakia
• Eva Rozborilova, Slovakia
• Peter Simko, Slovakia
• Ruzena Hlacova, Slovakia

ORGANIZING COMMITTEE
• Ivan Solovic, Slovakia
• Marta Hajkova, Slovakia
• Helena Leschtsirnova, Slovakia
• Deniska Kavkova, Slovakia
• Stefan Lassan, Slovakia
• Anna Lesnakova, Slovakia
• Jana Svecova, Slovakia
• Vladimir Littva, Slovakia
• Lukas Kober, Slovakia

CO-ORGANIZERS
• Slovak Medical Association
• Slovak pneumological and fibroleological association of the Slovak Medical Association
• National Institute for TB, Lung Diseases and Thoracic Surgery, Vysne Hagy

ACADEMIC INSTITUTION
• Slovak Medical University, Bratislava
• Catholic University, Ružomberok
Thanks to everyone who participated in the preparation and implementation of the conference.

Thanks to the association of Medical Students of the Slovak Medical University for their assistance provided during the conference.
HE Andrej Kiska  
President of the Slovak Republic

Jane Carter  
President The International Union Against Tuberculosis and Lung Disease

Ivan Solovic  
President The International Union Against Tuberculosis and Lung Disease

Tomas Drucker  
Minister of Health of the Slovak Republic

Zsuzsana Jakab  
WHO Regional Director for Europe

Mario Raviglione  
Director of the Global Tuberculosis Programme WHO

Marieke van der Werf  
The Head of the Disease Programme Tuberculosis ECDC

Lucía Díaz  
Executive Director of the Stop TB Partnership

Marta Hajkova  
Main Specialist of the MoH for TB and Lung Diseases, Slovakia

E. Jane Carter (USA), President The International Union Against Tuberculosis and Lung Disease

E. Jane Carter has focused her career on TB and is both an Associate Professor of Medicine at Brown University (USA) and Director of the Brown Kenya Medical Exchange Programme at Moi University (Kenya). She has been a Union member since 1990.

Zsuzsanna Jakab is the WHO Regional Director for Europe since February 2010, and was recently re-elected for her second term. Prior, Dr Jakab served as the founding Director of the European Union's European Centre for Disease Prevention and Control (ECDC) in Stockholm. Between 2002 and 2005, she was State Secretary at the Hungarian Ministry of Health, Social and Family Affairs, where she managed the country's preparations for European Union accession in the area of public health. Between 1991 and 2002, she worked at the WHO/Europe in a range of senior management roles. Dr Jakab holds a PhD degree in Health Sciences from the University of Debrecen; a Master's degree from the Faculty of Humanities, Eötvös Lóránd University, Budapest; a postgraduate degree from the University of Political Sciences, Budapest; a diploma in public health from the Nordic School of Public Health, Gothenburg, and a postgraduate diploma from the National Institute of Public Administration and Management, Hungary. She began her career in Hungary’s Ministry of Health and Social Welfare in 1975.
Mario C. Raviglione, M.D., FRCP (London), F.E.R.S.  
End TB – global situation and a new strategy in the SDG era

Mario C. Raviglione has been Director of the Global Tuberculosis Programme at the World Health Organization (WHO) since 2003. He contributed to the development of the DOTS strategy in 1994, set up the global drug-resistance surveillance project and the global TB surveillance & monitoring system, and directed the development of the Stop TB Strategy in 2006 and of the End TB Strategy in 2014. He is responsible for setting norms, policies and standards on global TB care and control, coordinating technical support to WHO Member States, monitoring the global situation, and developing innovative interventions through translation of new evidence into policies & practice. He has worked in many countries world-wide, has received international awards for his work on TB, and has served as visiting professor in universities in Italy, Switzerland and the USA. He has published over 350 articles and chapters on the topics of infectious diseases, HIV/AIDS and TB in influential health journals and books, including in the last six editions of the Harrison’s Principles of Internal Medicine, and has edited the 3rd and 4th edition (2006, 2009) of the reference book “Tuberculosis - A comprehensive International Approach”. His h-index is 87. He graduated from the University of Turin in Italy, and trained in internal medicine and infectious diseases in New York (where he was Chief Medical Resident at Cabrini’s Medical Centre) and Boston, where he was appointed an AIDS Clinical Research Fellow at Beth Israel Hospital, Harvard Medical School.

Giovanni Battista Migliori, European Respiratory Society Secretary General  
The ERS/WHO/UNION ER survey on management practices on refugees in European Region

Giovanni Battista Migliori is specialist in Respiratory Medicine and Medical Statistics, and Auditor of Quality Systems and is ERS Secretary General. With more than 20 years of experience in design, implementation and Monitoring Evaluation of TB and TB/HIV control programmes globally. He is Head of Clinical Epidemiology of Respiratory Diseases Service and Director of the World Health Organization (WHO) Collaborating Centre for TB and Lung Diseases at Fondazione S. Maugeri, Tradate, Italy active in TB control, training and research activities at the global level. He was elected a Fellow of the Royal College of Physicians (FRCP), London in 2012 (honorary nomination, bye-law 39b) and Foundation Fellow of the European Respiratory Society (FERS) in 2014.

Marieke J. van der Werf, MD, Ph.D., MSc, MPH  
Prevention and control of tuberculosis in the European Union: Where do we come from, where are we, and where are we going?

Marieke J. van der Werf is the head of the Disease Programme TB at the European Centre for Disease Prevention and Control since 2012 where she is responsible for the scientific and technical work of the Centre on TB surveillance, diagnosis, guidance development, and country support. She was trained as a medical doctor, in biomedical sciences, and in public health. She obtained her PhD. in 2003 and published more than 150 articles in international peer-reviewed journals. She has worked in Europe, Africa and Asia and provided technical assistance and built capacity for epidemiological and operational research on topics relevant for TB prevention and control. She participated in international policy and guidelines development groups, such as the World Health Organization STAG-TB and the Task Force Impact Measurement.

Lee B Reichman MD MPH  
The Tuberculosis Taboo

Lee B Reichman MD MPH is the Founding Executive Director of the Rutgers Global Tuberculosis Institute, and Professor of Medicine and Epidemiology at Rutgers New Jersey Medical School, in Newark New Jersey, USA. His distinguished career spans 45 years as TB Program Director (New York City); Pulmonary Medicine Division Director (Rutgers New Jersey Medical School); and global service as clinician, educator, consultant and advocate, many with WHO and The Union.
**KEYNOTE SPEAKERS**

**Knut Lönnroth**  
From stopping to ending and eliminating TB—What does it mean and how can it be done  
Knut Lönnroth is a Swedish medical doctor specialized in social medicine. He has a public health PhD from the Nordic School of Public Health and is associate professor of social medicine at the University of Gothenburg. He has done extensive research on health systems and social aspects of health with a particular focus on TB. He has worked for WHO for the past 10 years and is currently focal person for social determinants, risk factors, TB co-morbidities, and TB screening in the Policy Strategy and Innovations unit of the Global TB programme.

**Martin van den Boom, MD, MSc PH,**  
Jointly tackling tuberculosis and strengthening health systems in the WHO European Region: possible contributions of a multi-partner project approach.  
He is originally from Germany, studied medicine and public health in Germany, Switzerland, France, the United States, United Kingdom and Spain. He is a graduate of the University of Aachen, where he also obtained his doctorate in medicine, and the London School of Hygiene and Tropical Medicine. He joined WHO in early 2008, after having worked several years in clinical medicine. Ever since he has been able to work in different technical areas of TB prevention and care in several WHO World Regions, having provided technical assistance to more than 40 WHO Member States, and been co-author of international peer-reviewed publications. His favorite areas of interest are the integration of TB in primary health care, TB relevant health system strengthening, childhood TB and X/MDR-TB.

**Viorel Soltan**  
Jointly tackling tuberculosis and strengthening health systems in the WHO European Region: possible contributions of a multi-partner project approach.  
Viorel Soltan works as Director of the Center for Health Policies and Studies (PAS Center) starting 2007 and during 2004–2007 he lead American International Health Alliance Moldova office. Before he served as Director of Public Health Programs at the Open Society Foundations for six years. During 2011 – 2012, Dr. Soltan served as First Deputy Minister of Health in Moldova. Currently he is Associate Professor at the School of Public Health in Moldova where teaches health systems and management. Dr. Soltan is a renowned international consultant with over thirty-five consultancy assignments related to health systems, TB and HIV control.

**Timothy R. Aksamit, MD**  
TB or non-TB (NTM)  
Timothy Aksamit is a Consultant and Associate Professor in the pulmonary disease and critical care medicine division of Mayo Clinic, Rochester, MN. Dr. Aksamit received his undergraduate degree in chemistry from the University of Illinois in Urbana, IL; medical degree from Northwestern University in Chicago, IL; and medical training in internal medicine as well as pulmonary and critical care medicine at the University of Iowa in Iowa City where he also was a chief resident. Prior to joining the staff at Mayo Clinic in 1998 he was in private practice in Madison, WI. Dr. Aksamit’s research and clinical interests have focused on mycobacterial disease and bronchiectasis. He has co-authored a previous international statement by the American Thoracic Society and Infectious Disease Society of America on the diagnosis and treatment of nontuberculous mycobacterial disease. He currently serves as chair of the U.S. Bronchiectasis Research Registry. Dr. Aksamit has served as medical director of Mayo Clinic Olmsted County Public Health department TB clinic, chair of the State of Minnesota Tuberculosis Advisory Committee, and medical director of the Mayo Mycobacterial and Bronchiectasis Clinic. Other interests include work as previous director of the medical intensive care unit, staff consultant in the pulmonary function laboratory as well as medical director of chaplain services.
**Wednesday, 22 June 2016**

**Hall A - Opera**
- 9.00 - 10.30: Václav Richter
- 10.30 - 11.15: Giovanni Battista Migliori, Alberto Matteelli
- 12.00 - 13.30: Vitešslav Kolka, Eva Rožborilová
- 13.30 - 15.00: Daniele Cirillo
- 15.30 - 17.00: Yvonne O'Mahony, Ien Schoub et al.
- 17.00 - 18.30: Heléntinga

**Hall B - Štúdio**
- 9.00 - 10.30: Denis Falzoni
- 10.30 - 12.00: Denis Falzoni
- 12.00 - 13.30: Denis Falzoni
- 13.30 - 15.00: Denis Falzoni
- 15.30 - 17.30: Denis Falzoni

**Hall C - Modrý saloník**
- 9.00 - 11.00: Patricia Ribeiro
- 11.00 - 12.00: Patricia Ribeiro
- 12.00 - 14.00: Patricia Ribeiro
- 14.00 - 15.00: Patricia Ribeiro
- 15.00 - 16.00: Patricia Ribeiro
- 16.00 - 17.00: Patricia Ribeiro

**Hall D - Činohra**
- 9.00 - 10.30: Račija Bhatwadi
- 10.30 - 12.00: Račija Bhatwadi
- 12.00 - 14.00: Račija Bhatwadi
- 14.00 - 15.00: Račija Bhatwadi
- 15.00 - 17.00: Račija Bhatwadi

**Hall E - Modrá obytná**
- 9.00 - 11.30: Slovak National Theatre
- 11.30 - 13.30: Slovak National Theatre
- 13.30 - 15.00: Slovak National Theatre
- 15.00 - 17.00: Slovak National Theatre

**Opening Ceremony**
- 17.30 - 18.30

---

**Thursday, 23 June 2016**

**Hall A - Opera**
- 8.30 - 10.00: Peter David, Martin Sokolik
- 10.00 - 10.30: Peter David, Martin Sokolik
- 10.30 - 12.00: Genevieve Antinou, Martin Chetrit
- 12.00 - 13.30: Christian Faerber
- 13.30 - 15.00: Christian Faerber
- 15.00 - 16.30: Christian Faerber
- 16.30 - 18.00: Christian Faerber

**Hall B - Štúdio**
- 8.30 - 10.00: Denis Falzoni
- 10.00 - 10.30: Denis Falzoni
- 10.30 - 12.00: Denis Falzoni
- 12.00 - 13.00: Denis Falzoni
- 13.00 - 15.00: Denis Falzoni
- 15.00 - 16.00: Denis Falzoni
- 16.00 - 17.30: Denis Falzoni

**Hall C - Modrý saloník**
- 8.30 - 10.00: Denis Falzoni
- 10.00 - 10.30: Denis Falzoni
- 10.30 - 12.00: Denis Falzoni
- 12.00 - 13.30: Denis Falzoni
- 13.30 - 15.00: Denis Falzoni
- 15.00 - 16.30: Denis Falzoni

**Hall D - Činohra**
- 8.30 - 9.15: Ruzena Tkáčová
- 9.15 - 10.30: Václav Richter
- 10.30 - 11.15: Martin Kudla
- 11.15 - 12.30: Václav Richter

**Hall E - Modrá obytná**
- 9.00 - 11.30: Slovak National Theatre
- 11.30 - 13.30: Slovak National Theatre
- 13.30 - 15.00: Slovak National Theatre
- 15.00 - 17.00: Slovak National Theatre

---

**Time Schedule**

**Wednesday, 22 June 2016**
- 17.00 - 18.30: Opening Ceremony

**Thursday, 23 June 2016**
- 17.00 - 18.30: Slovak National Theatre
WEDNESDAY | 22 JUNE 2016

7th CONFERENCE OF THE UNION EUROPE REGION
SLOVAK NATIONAL THEATRE • Bratislava, Slovakia • 22 – 24 June 2016
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
</tr>
</thead>
</table>
| 9:00 – 17:00 | **MEDICAL MANAGEMENT CHALLENGES IN TUBERCULOSIS CARE**  
Post-Graduate Course  
Coordinator: Rajita Bhavaraju  
Faculty: Neil Schluger and Ignacio Monedero  
- 09:00 – 09:15     Introductions, course objectives, pre-test, and housekeeping  
- 09:15 – 10:00     Overview of treatment and medical management challenges for TB  
- 10:00 – 11:00     Diagnosis and Management of TB in Persons Living with HIV  
- 11:00 – 11:30     Coffee break  
- 11:30 – 12:30     Treatment of Latent TB Infection and Active TB in Solid Organ Transplant Candidates and Recipients  
- 12:30 – 13:30     Lunch  
- 13:30 – 14:30     Effects of TNF-alpha inhibitors and Screening for Latent TB Infection  
- 14:30 – 15:30     TB and Diabetes Co-Management  
- 15:30 – 16:00     Coffee break  
- 16:00 – 16:45     Case presentations  
- 16:45            Post-test, evaluation, and adjourn |
| 9:00 – 16:00 | **HOW TO PERFORM CONTACT INVESTIGATION**  
Post-Graduate Training  
Coordinator: Niesje Jansen, Connie Erkens  
- 09:00 – 10:00     Introduction Leading principles of contact investigation in low incidence setting  
- 10:00 – 10:30     When to perform contact investigation  
- 10:45 – 11:30     Data collection  
- 11:30 – 12:30     Group work:  
  - In which cases is contact investigation needed?  
  - Which contacts are eligible for investigation?  
  - How and when should contacts be examined?  
- 12:30 – 13:00     Organization and timing of evaluation of priority groups  
- 13:00 – 14:00     Lunch  
- 14:00 – 15:00     TB Outbreaks and when to scale up to lower priority contacts  
- 15:00 – 15:15     Coffee break  
- 15:15 – 16:00     Opportunities and pitfalls of introducing advanced contact investigation practices in medium / high incident settings  
17:00 – 18:30 | OPENING CEREMONY • HALL A • OPERA |
8.30 - 11.30 TRANSFORMING AND OPTIMIZING PATIENT-CENTRED MODELS OF TB CARE IN COUNTRIES OF THE FORMER SOVIET UNION (FSU)
Coordinator(s): Valiantsin Rusovich (Belarus)
Chairman: Masoud Dara, Alena Skrahina

1. Masoud Dara
Implementation of TBREP project (health system reform project funded by GFATM) in WHO European Region (Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan, Ukraine, Uzbekistan.) 20’

2. Irina Vasilyeva
Chemotherapy of TB and drug resistant TB in Russian Federation: challenges and new opportunities 20’

3. Aliaksandr Skrahin
Autologous mesenchymal stromal cell infusion as adjunct treatment in patients with M/XDR-TB 20’

4. Iana Terleieva
Tuberculosis control in Ukraine: achievements and challenges 20’

5. Nargiza Parpieva, Mirzagolib Tillyashkeyhov
Experience of Uzbekistan in wide-scale policy changes on TB 20’

6. Armen Hayrapetyan
Finance reform in Armenia: achievements and challenges 20’

12.00 – 13.30 PLENARY LECTURES
Chairman(s): Jane Carter, Marta Hajkova

Giovanni Battista Migliori
The ERS/WHO/UNION and ER survey on management practices on refugees in European Region

Marieke van der Werf
Prevention and control of tuberculosis in the European Union: Where do we come from, where are we, and where are we going?

Lee B. Reichman
The Tuberculosis Taboo
program • thursday 23 june 2016

hall A - opera


coordinator(s): malgorzata grzemska (switzerland), martin van den boom (denmark)
chairmen(s): malgorzata grzemska and martin van den boom

10. bobis sismanidis and martin van den boom
estimates of mdr-tb burden among children and adolescents (global and european perspective) 25’

11. malgorzata grzemska
who policy guidance on mdr-tb in children and research gaps 25’

12. anna turkova
prevention of mdr-tb in children and adolescents 25’

13. iveta ozere
diagnosis and treatment of mdr-tb in children and adolescents 25’

14. philippe du cros
drug resistant tb programmes for children in central asia 25’

15. ernesto jaramillo / gunta dravniece
ethical issues 25’

discussion on challenges and the way forward
panel of all speakers 30’

17:00 - 17:45 experiences from the tb reach initiative in improving tb care

coordinator(s): jacob creswell (switzerland) and andrew codlin (switzerland)
chairmen(s): maya kavtaradze and jacob creswell

16. andrew codlin
overview of tb reach waves 1–4 and monitoring & evaluation framework 10’

17. katya gamazina
a new model for early diagnosis and treatment of tb in pre-trial detention centres (sizos) in ukraine 10’

18. cristina celan
scaling up xpert mtb/rif testing to improve drug-sensitive and -resistant tb detection in moldova 10’

19. farangiz mirzoeva
improving tb notification through screening and innovative approaches 10’
8:30 – 10:00

CASE PRESENTATIONS IN CLINICAL TUBERCULOSIS
Coordinators: Peter Davies (UK), Martin Dedicoat (UK)
Chairmen: Peter Davies, Martin Dedicoat

Speakers:
20. Martin Dedicoat
21. On Min Kon
22. Gerrit Woltmann
23. Jo Keane

10:30 – 12:00

MANAGEMENT OF LATENT TUBERCULOSIS INFECTION: FROM POLICY TO IMPLEMENTATION
Coordinators: Giovanni Battista Migliori (Italy) Alberto Matteelli (Italy)
Chairmen: Giovanni Battista Migliori, Daniela Cirillo

24. Giovanni Battista Migliori
What is new in the END TB Strategy to support TB Elimination: the prevention package
20’

25. Giovanni Setgliu
Monitoring and evaluation guide for LTBI activities
20’

26. Alberto Matteelli
LTBI testing and treatment in immigrants in Europe
20’

27. Enrico Girardi
Diagnostic tools for LTBI: what we have and what we need
20’

13:30 – 15:00

RISK GROUP APPROACHES: BEST PRACTICES IN TB-CONTROL IN A HIGH INCOME, LOW BURDEN COUNTRY MOVING TO TB ELIMINATION
Coordinators: Connie Erkens (Netherlands)

28. Gerard de Vries
National TB Control Plan 2016-2020: towards TB elimination
15’

29. Connie Erkens
Risk group policy: from active case finding towards screening for latent infection
15’

30. Job van Rest
Evaluating the effectiveness of contact investigation and risk group interventions
15’

31. Niesje Jansen
Patient centered care and the role of the TB nurse
15’

32. Rianne van Hunen
TB among health care workers
15’

All speakers
Discussion
15’
15:30 – 17:30  VARIOUS PROBLEMS TO COMBAT TUBERCULOSIS AND LUNG DISEASES
Chairmen: Vitezslav Kolek (Czech Republic) and Eva Rozborilova (Slovakia)

33. Vitezslav Kolek
Organizational changes in the care of TB in the Czech Republic in recent years. 15'

34. Rudolf Rumetschofer
Tuberculosis treatment in Vienna by multi-professional teamwork 15'

35. Martin Brezina
Diseminated tuberculosis complicated by concomitant infection with Mycoplasma pneumoniae, Pneumocystis jiroveci and Rothia mucilaginosa in 7 month old child 15'

36. Katarína Mikusová
Lack of new drugs and how to address it; benzothiazinones – a case study from New/More Medicines for Tuberculosis consortia 20'

37. Reinhardt Flo (Medical Advisor GSK Norway)
Factors in HIV pathogenesis and medication of particular importance to lung health 20'

38. *

8:30 – 10:00  UPDATE ON DRUG SENSITIVITY TESTS FOR M. TUBERCULOSIS
Coordinator(s): Daniela Cirillo
Chairmen(s): Emanuele Borroni, Herald Hoffman

39. Leen Rigouts
How to test M. tuberculosis complex strains for bedaquiline 20'

40. Herald Hoffman
How to test M. tuberculosis complex strains for Delamanid 20'

41. Angela Starks
Evaluation of commercial mic plates for testing M. tuberculosis sensitivity 20'

42. T. Walker /C.Lange
The clinician prospective: can availability of mic data contributing to improve the management of MDR/XDR TB patients 20'

10:30 – 12:00  PUBLIC HEALTH’S GREATEST CHALLENGE? SUSTAINABLE FUNDING?
Coordinator(s): Ehsan Latif (UK)
Chairmen(s): Andrew Black (UK)

43. Andrew Black
Public Health in Europe – the funding challenge 20'

44. Ibrahim Abubakar
TB funding, challenges and solutions 20'
| 45. Ehsan Latif | A Global Perspective on Sustainable Fund Models for Public Health | 20’ |
| 46. Lela Sturua | Developing a national health promotion fund | 20’ |
| *38. Els Hollanders (Medical Director Alliance Countries ViiV) | ViiV – introduction, R&D direction in HIV | 20’ |

**DIGITAL HEALTH IN SUPPORT OF TB PATIENTS AND PROFESSIONALS**

Coordinator(s): Dennis Falzon (Switzerland)  
Chairmen(s): Viorel Soltan, Dennis Falzon  
Facilitator(s): Giovanni Battista Migliori, Jean-Pierre Zeitweber

| 47. Ibrahim Abubakar | State of the evidence for digital health concepts in TB care and prevention | 15’ |
| 48. Alistair Story | Video observed therapy for TB patients: its impact, its promise | 15’ |
| 49. Andrei Dadu | Case studies from eastern Europe | 15’ |
| 50. Ivan Solovic | Explain TB, and other TB eLearning apps for mobile phones | 15’ |
| 51. Gini Arnold | Be Healthy, Be Mobile: a platform for action on tobacco and other non-communicable disease | 15’ |
| 52. Dennis Falzon | The WHO/ERS agenda for action | 15’ |

| 53. Dyah Erti Mustikawati | Integration of TB screening into national diabetes control program-Indonesia experience | 15’ |
| 54. Richard Brostrom | Experience of DM-TB collaboration in Pacific Islands Countries | 15’ |
| 55. Yanli Yuan | Integration of blood sugar monitoring into existing TB service: Are we ready? Experience from sub-national level | 15’ |
| 56. Jing Bao | Confronting the growing DM TB epidemic – NIH initiative | 15’ |
| 57. Yan Lin | How to move forward on implement screening of DM patients for TB | 15’ |

Panel Discussion

Active Case-finding for TB in your DM Clinics: Who to Screen, How to Screen, When to Screen 15’
### Program Thursday 23 June 2016

**Hall C - Modrý Salónik**

**17:00 – 18:30**

**Isoniazid-resistant tuberculosis in Europe - a topic of concern?**

**Coordinator(s):** Helen Stagg (UK)  
**Chairmen(s):** Piret Viiklepp, Gerard de Vries

1. Helen Jenkins  
   Isoniazid resistant tuberculosis - why is it important?  
   15’

2. Helen Stagg  
   Chemoprophylaxis and treatment: is isoniazid resistance of concern?  
   15’

3. Alena Skrahina  
   Isoniazid resistance in a setting of high MDR-TB prevalence: an example from Belarus.  
   15’

---

**Hall D - Činohra**

**8:30 – 9:15**

**Idiopathic pulmonary fibrosis. From diagnosis to treatment**

**Coordinator(s):** Martina Vassakova (Czech Republic)  
**Chairmen(s):** Martina Vassakova, Wim Wuyts, Eva Kocova

41. Martina Vassakova  
   What is new in diagnosis of idiopathic pulmonary fibrosis?  
   15’

42. Eva Kocova  
   Role of radiologist in diagnosis of idiopathic pulmonary fibrosis  
   15’

43. Robert Vysehradsky  
   Current treatment of idiopathic pulmonary fibrosis. Guidelines and real life.  
   15’

---

**9:15 – 10:00**

**Management exacerbations respiratory infections I.**

**Chairmen(s):** Ivan Majer, Helena Leščišinová

44. Denisa Kavková  
   Majú bakteriálne lyzáty miesto v prevencii akútnych exacerbácií CHOOP?  
   15’

45. Marta Hájková  
   Používanie viacerých inhalačných systémov može byť pre pacientov zmätočné  
   15’

*46. Helena Novosadová  
   Inozín pranox in pneumologické praxi.*  
   10’

*47. Zuzana Homolová  
   Lactobacillus reuteri a jeho využitie v pneumologické praxi.*  
   10’

**Discussion**
10:30 – 11:15
AKO ZMENIA NAJNOVŠIE POZNATKY LIEČBU PACIENTOV S CHOCHP S RIZIKOM EXACERBÁCIÍ
Coordinator(s): Ružena Tkáčová

66. Ružena Tkáčová
Vývoj poznania akútnych exacerbácií CHOCHP

67. Bohumil Matula
Výsledky štúdie FLAME: Kto obstál v skúške ohňom?.

11:15 – 12:00
JEDNA LIEČBA – DVA POHĽADY
Coordinator(s): Marta Hajkóvá

68. Svetlana Hadrová
Komplexná účinnosť anti-IgE liečby z pohľadu klinika

69. Mária Andrášiová
Ako vníma svoju liečbu pacient s šäzkou astmou

13:30 – 15:00
INNOVATIVE TREATMENT OF RESPIRATORY DISEASES
Chairmen(s): Marta Hajkóvá

70. Ruzena Tkacova
Novel perspectives in COPD management

15:00 – 16:00
DOZRUEL ČAS NA ZMENU PARADIGMY LIEČBY CHOCHP?
Coordinator(s): Ružena Tkáčová
Chairman(s): Thys van der Molen (Netherlands)

71. Arschang Valipour
Scientific evidence and clinical experience with Tiotropium/Olodaterol Respinmat therapy in patients with COPD

72. Stefan Lassan
IPF diagnosis, management, treatment and awareness in Slovakia

73. Thys van der Molen
Symptoms & physical activity in COPD patients

74. Štefan Laššán
Ako optimalizovať farmakologickú liečbu CHOCHP? Nový pohľad na bronchodilaťačné a protizápalovú termiop.

75. Ružena Tkáčová
Eosinofília a bronchiálna hyperreaktivita – indikátor k liečbe ICS?

16:00 – 16:45
EXPERT’S OPINION ON CONTROVERSIES IN COPD
Coordinator(s): Stefan Lassan
Chairmen(s): Ronald Dahl (UK)

76. Stefan Lassan
Scientific evidence and clinical experience with Tiotropium/Olodaterol Respinmat therapy in patients with COPD

78. Thys van der Molen (Netherlands)
Symptoms & physical activity in COPD patients

79. Ronald Dahl (UK)
Symptoms & physical activity in COPD patients
17:00 – 17:45  SLEEP DISORDERED BREATHING AND COMORBIDITIES: ROLE OF NIV

Coordinator(s): Ruzena Tkacova (Slovakia)

76. Zuzana Kuklisova
Noninvasive ventilation in patients with OSA and COPD  15’

77. Ruzena Tkacova
Sleep-disordered breathing and cardiovascular comorbidities  15’

Diskusia  15’
NEW TECHNOLOGIES IN TB DIAGNOSIS AND TB TREATMENT IN CONDITIONS OF IMMIGRATION GAIN. EXPERIENCE IN RUSSIA.

Coordinator(s): Starshinova Anna (Russian Federation)
Chairmen: P. Yablonskiy, E. Bogorodskaya

78. E. Bogorodskaya
Organization of TB detection in urban metropolitan conditions 15'

79. S. Borisov, A. Filippov, D. Ivanova, T. Ivanushkina, N. Litvinova
Chemotherapy regimens of tuberculosis, including new antituberculosis drugs – an experience on creating and implementing 15'

80. P. Yablonskiy, I. Vasilyev, G. Marfina, G. Kudriashov, A. Avetisian
New surgical methods in TB diagnosis and TB treatment of lungs 15'

81. V. Zhuravlev, A. Mushkin, N. Solovieva, E. Chernyaeva, A. Vyazovaya, D. Zimenkov
Modern diagnostic capabilities, verification and treatment of extra pulmonary tuberculosis as an example of bones and joints injuries 15'

82. A. Starshinova, E. Istromina, V. Manina, A. Panteveev, E. Vasilyeva, M. Pavlova
Possibilities of different immunological methods in LTBI diagnosis 15'

EXPANDING NEW DIAGNOSTIC FOR TB PROJECT. RAPID AND EARLY TB DIAGNOSIS: ESTABLISHING NEW DIAGNOSTIC PLATFORMS AND ROLL OUT OF NEW TB DIAGNOSTICS IN COUNTRIES OF EASTERN EUROPE—EXPANDING NEW DIAGNOSTICS FOR TB PROJECT

Coordinator(s): Fuad Mirzayev (Switzerland)
Chairmen: Fuad Mirzayev, Harald Hofmann

83. Maka Akhalia, Fuad Mirzayev
Expanding Access to New TB diagnostic – EXAND – TB Project achievements, challenges and lessons learnt 15'

84. Elena Romancenco
Expand – TB project in Moldova: current status, achievements and challenges 15'

85. Gulmira Kalmambetova
EXPAND – TB project Kyrgyzstan: focus on transition 15'

86. Nargiza Parpieva
EXPAND – TB project in the penitentiary sector in Azerbaijan: current status, achievements and challenges 15'

87. Oktam Bobokhodjaev
Impact of rapid diagnostics on patient management in high burden and low income countries, Examples from the clinical practice in Tajikistan 15'
12:00 – 13:30     **PLENARY LECTURES**

**Chairmen(s):** Lucica Ditiu, Martin Brezina

Knut Lonnroth
From stopping to ending and eliminating TB-What does it mean and how can it be done

Martin van den Boom
Jointly tackling tuberculosis and strengthening health systems: extraordinary possibility for multi-partner approach in the WHO European Region

Timothy Askamit
TB or non-TB (NTM)?

**13:30 – 15:00     A PROGRAMMATIC APPROACH TO THE RIGHT DIAGNOSTICS AND THE RIGHT TREATMENT: THE KNCV TUBERCULOSIS FOUNDATION EXPERIENCE**

**Coordinator(s):** Connie Erkens (Netherlands)

88. Maria Idrissova
Treatment options: something old, something new 10’

89. Nick Blok
The shortest way to a correct diagnosis: the treatment triaging approach 10’

90. Maria Idrissova
Patient safety: KNCV approach in WHO EURO region (CAR countries) 10’

15:30 – 17:00     **ROAD TO BRATISLAVA 2016: A UNITING CALL FROM TB AND HIV STAKEHOLDERS FOR EUROPEAN POLITICAL LEADERSHIP IN THE FIGHT AGAINST COMMUNICABLE DISEASES.**

**Organisers(s):** The TB Europe Coalition

**Chairmen(s):** Fanny Volzewinkler, Andrey Klepikov

91. Olga Pavlova / Merkinal Sulaimanova
The KNCV approach: illustrative country examples:
- Programmatic preparations for introduction, Monitoring and PV
- Drug Management

92. Nick Blok
Evidence for change: feasibility and effectiveness 10’

All speakers
Discussion: How can countries move forward towards responsible programmatic use of the novel diagnostic and treatment opportunities 25’

93. Lucica Ditiu
Walking the talk: putting TB and HIV back at the top of the European political agenda 15’

94. Martin van den Boom
Regional perspectives: Supporting countries’ political leadership in the fight against TB & HIV 15’

95. George Khechinashvili
The role of parliamentarians in the fight against TB in Europe 15’
96. Slovak government representative (tbc)
   Slovak leadership in the fight against communicable diseases in Europe:
   EU Presidency 2016

97. Timur Abdullaev
   Uniting TB and HIV communities in political advocacy: better results for those
   who need it most 15'

98. Nicolas Cantau
   Funding sustainable response to communicable diseases in the European region:
   a shared responsibility 15'

99. Sergey Votyagov
   The way forward: responding to challenges in TB, HIV and harm reduction in the
   European region 15'

17:00 - 18:00     CLOSING CEREMONY

Jane Carter, Ivan Solovic, José Castro, Lucica Ditiu, TB Caucus
<table>
<thead>
<tr>
<th>Time</th>
<th>MDR-TB</th>
</tr>
</thead>
</table>
| 10:30 – 12:00 | Coordinator(s): Raquel Duarte (Portugal)  
Chair: J.P. Zellweger and G. Sotgiu                                                                                  |

| 106. | Denis Falzon  
Multidrug-resistant tuberculosis: current and future needs? 20' |
| 107. | Christoph Lange  
Management of patients with multidrug-resistant tuberculosis 20' |
| 108. | Raquel Duarte  
Management of contacts of multidrug-resistant patients 20' |
| 109. | Ernesto Jaramillo  
Past, present and future of palliative care 20' |

<table>
<thead>
<tr>
<th>13:30 – 15:00</th>
<th>CONTACT INVESTIGATION FOR TB IN EUROPE</th>
</tr>
</thead>
</table>
| Coordinator(s): Jean-Pierre Zellweger (Switzerland)  
Chairmen(s): Ivan Solovic, Maryse Marinin                                                                                       |
| 110. | Jean-Pierre Zellweger  
The TB-NET study on contact investigation 20' |
| 111. | Nicole Ritz  
Detection of TB infection in children 20' |
| 112. | Morten Ruhwald  
New tools for the detection of LTBI 20' |
| 113. | Rosa Sloot  
Screening for LTBI: useful activity or waste of resources? 20' |

---

**Friday 24 June 2016**

**Hall B - Štúdio**

### TOPIC ON MDR/TB IN EUROPE – TB NET SYMPOSIUM

**Coordinator(s): Christoph Lange (Germany)**

<table>
<thead>
<tr>
<th>Time</th>
<th>Presentation</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 – 10:00</td>
<td>TOPIC ON MDR/TB IN EUROPE – TB NET SYMPOSIUM</td>
</tr>
</tbody>
</table>
| 100. | Graham Bothamley  
TBNET: A Clinical Research Collaboration with the European Respiratory Society on MDR-TB 10' |
| 101. | Martina Sester  
Numbers needed to treat to prevent TB 10' |
| 102. | Günther Gunar  
Levels of M. tuberculosis drug resistance and treatment outcomes in European adults: Results from the TBNET cohort study 10' |
| 103. | Daniela Cirillo  
Clinical implications of molecular drug resistance testing in MDR-TB: A TBNET and RESIST-TB consensus statement 10' |
| 104. | Frank v Leth  
Cost of drugs for MDR-TB as an indicator for healthcare inequalities in Europe: A TBNET survey 10' |
| 105. | Christoph Lange  
Management of patients with MDR-TB in Europe: A TBNET consensus statement 10' |
15:30 – 17:00  HANDLING UNEXPECTED COPD

Coordinator(s): Jean-Pierre Zellweger (Switzerland)

Chairmen: Stefan Lassan, Jean-Pierre Zellweger

114. Jean-Pierre Zellweger
Smoking, indoor air pollution and tuberculosis 20’

115. Tamara Schikowski
Ambient air pollution and COPD 20’

116. Isabella Annesi-Maesano
Indoor air pollution: a risk for COPD in Europe? 20’

117. Jean-William Fitting
Which lung function test for the general practitioner? 20’

8:30 – 10:00  ETHICS AND HUMAN RIGHTS: WHY THEY MATTER IN TUBERCULOSIS

Coordinator(s): Nisha Ahamed

Faculty: Nisha Ahamed, Stéphanie Dagron, Ernesto Jaramillo, Lee Reichman

118. Lee Reichman
Introduction 10’

119. Ernesto Jaramillo
Overview of ethics and human rights around TB, current challenges and WHO guidance 30’

120. Stéphanie Dagron
Experiences with legal assistance from the European region 20’

121. Nisha Ahamed
Resources: Ethics assessment tool for TB programmes and training curriculum 10’

Panel Discussion 15’

10:30 – 12:00  INTEGRATING MOLECULAR TYPING AND SEQUENCING INTO ROUTINE SURVEILLANCE AND CONTROL OF TUBERCULOSIS

Coordinator(s): Barbara Hauer (Germany), Ibrahim Abubakar (UK)

Chairmen: Walter Haas, Ibrahim Abubakar

122. Stefan Niemann
Molecular typing and sequencing for tuberculosis surveillance and control: Background, challenges and limitations 20’
123. Gerard De Vries  
The Dutch story of molecular epidemiology in TB surveillance  20'

124. Lucy Thomas  
Molecular typing in the UK and public health implications for whole genome sequencing for TB  20'

125. Lena Fiebig  
A joint cross-border investigation of a molecular MDR-TB cluster in Romania, Austria and Germany: Lessons learnt  20'

13:30 – 15:00  
PROMOTING A COMPREHENSIVE RESPONSE TO HIV/TB CO-INFECTION IN WHO EUROPE REGION: THE COMMUNITY PERSPECTIVE

Coordinators: Timur Abdullaev (Uzbekistan)

126. Gunta Dravniece  
Treatment options: something old, something new  10'

127. Agnes Gebhard  
The shortest way to a correct diagnosis: the treatment triaging approach  10'

128. Gunta Dravniece  
Patient safety: KNCV approach in WHO EURO region (CAR countries)  10'

129. Katya Gamazina, Mavlida Makhmudova, Bakyt Myrzaliev  
Programmatic preparations for introduction, Drug management, Monitoring and PV 25'

130. Susan van den Hof  
Evidence for change: feasibility and effectiveness  10'

All speakers  
Discussion: How can countries move forward towards responsible programmatic use of the novel diagnostic and treatment opportunities

ADDRESSING MAJOR CHALLENGES IN TB CONTROL IN UKRAINE

Coordinators: Olga Pavlova (Ukraine)

131. PATH  
Integrated tuberculosis and HIV care in Ukraine: impact of early ART on mortality rate among people co-infected with TB and HIV  15'

132. PATH  
Results of infection control implementation in TB facilities in Ukraine instead of Three I’s implementation in the 2 oblasts of Ukraine: results and lessons learnt  15'

133. NTP  
Using the e-TB manager for programmatic management of TB in Ukraine  15'

134. A. I. Barbova  
Prevalence of drug resistant strains of MBT in Ukraine: data national drug resistance survey 2014  15'

135. N. A. Litvinenko, L. Yu. Markovtsy  
Clinical and economic efficiency of the treatment of patients with MDR/XDRTB requiring inpatients observation: achievement and perspectives  15'

136. G. Popescu, I. Prasacu  
Socially oriented project Protection of children against tuberculosis: the experience of optimization of the system to identify the tuberculosis contact children up to 5 years and chemoprophylaxis children's forms of isoniazid  15'
8:30 – 10:00  MANAŽMENT EXACERBÁCIÍ RESPIRÁCNÝCH OCHORENÍ II.
Chairmen: Karol Králinský, Ivan Majer

137. Karol Králinský
Očkovanie proti pneumokokom na Slovensku: Kde sme dnes? 15'
Prednáška je podporená spoločnosťou Pfizer

138. Jan Chlumský
Treatin of COPD due to alpha-1 antitrypsin deficiency in the Czech republic 15'

139. Štefan Laššán
Výhody a úskaša duálné bronchodilatácie podávanej 2x denne 15'

140. Marta Hajková
Aký pohľad priniesli klinické štúdie na fixnú kombináciu aklidínium/formoterol? 15'

141. Eva Goncalesová
Principy diagnostiky a liečby príčinnej artérie hypernzie 15'

10:30 – 11:15  SCREENING FOR LATENT TUBERCULOSIS IS EFFECTIVE BUT DOES NOT FULLY PROTECT AGAINST TUBERCULOSIS REACTIVATION DURING ANTITNF TREATMENT IN AREAS WITH HIGH BACKGROUND INCIDENCE OF TUBERCULOSIS
Coordinator(s): Zuzana Zelinkova (Slovakia)
Chairmen: Zuzana Zelinková

142. Zuzana Zelinkova
Impact on concomitant immune suppression on the efficacy of screening for latent tuberculosis in inflammatory bowel disease prior anti-tumor necrosis factor therapy 45'

11:15 – 12:00  PNEUMOCOCCAL VACCINATION - ONE OF THE MOST SUCCESSFUL PUBLIC HEALTH MEASURES
Chairmen: Ivan Solovic
 symposium je podporené z finančného príspevku spoločnosti Pfizer

143. Pavol Papay
Screening for LTB in an immunocompromised host - lessons from HIV patients' population

144. Ron Dagan
The impact of pneumococcal conjugated vaccines on public health 45'

13:30 – 15:00  TB IN SPECIAL POPULATIONS
Coordinator(s): Zohar Mor (Israel)
Chairmen: Zohar Mor, Dara Masoud

145. Alberto Matteelli
TB prevention in asylum seekers entering Italy 15'

146. Pierpaolo de Colombani
TB in European prisons: current epidemiology and trends 15'

147. Lena Fiebig
Tuberculosis in Germany: a declining trend coming to an end? 15'

148. Ivan Solovic
TB in Roma people 15'

149. Zohar Mor
TB in Israeli migrants 15'
Run for Healthy Lungs – Beh za zdRavé plůca, 22. 6. 2016 at 8:30 pm

Join the Run for healthy lungs!
Evening Run: 4.2 km
Start place: Shopping center Eurovea
Date: 22. 6. 2016
Time: 20:30
Enjoy running along the Danube with a beautiful panoramic view!

Bratislava, St. Martin’s Cathedral, 23 June 2016 at 8:00 pm

Concert by Teachers and Students of the Music Department, Faculty of Education, Catholic University in Ružomberok

Organization Team Conference

Jana Chrenková +421 911 454 298 jana.chrenkova@tajpan.com
Jozef Naňo +421 903 454 294 jozef.nano@tajpan.com
Peter Slovak +421 911 454 294 peter.slovak@tajpan.com
Martin Maník +421 911 454 296 martin.manik@tajpan.com

Registration Fees

<table>
<thead>
<tr>
<th>Service</th>
<th>NON UNION MEMBER</th>
<th>UNION MEMBER</th>
<th>ACCOMPANYING PERSON</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration until 31. 6. 2016</td>
<td>350 €</td>
<td>300 €</td>
<td>80 €</td>
</tr>
<tr>
<td>Registration from 1. 6. 2016</td>
<td>400 €</td>
<td>350 €</td>
<td>120 €</td>
</tr>
<tr>
<td>Register on the spot</td>
<td>450 €</td>
<td>400 €</td>
<td>120 €</td>
</tr>
<tr>
<td>One Day Registration</td>
<td>120 €</td>
<td>100 €</td>
<td>50 €</td>
</tr>
</tbody>
</table>

- student in training or participants under 35 years old 100 €
- nurse, paramedic, civil society member, non medical member 100 €

Social Program General Information

<table>
<thead>
<tr>
<th>Category</th>
<th>NON UNION MEMBER</th>
<th>UNION MEMBER</th>
<th>ACCOMPANYING PERSON</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration until 31. 6. 2016</td>
<td>350 €</td>
<td>300 €</td>
<td>80 €</td>
</tr>
<tr>
<td>Registration from 1. 6. 2016</td>
<td>400 €</td>
<td>350 €</td>
<td>120 €</td>
</tr>
<tr>
<td>Registration on the spot</td>
<td>450 €</td>
<td>400 €</td>
<td>120 €</td>
</tr>
<tr>
<td>One Day Registration</td>
<td>120 €</td>
<td>100 €</td>
<td>50 €</td>
</tr>
</tbody>
</table>

Registration Fee Should Be Paid to Account Number Below

Bank: UniCredit Bank Czech Republic and Slovakia, a.s., pobočka zahraničnej banky
Bank address: Šancová 1/A, 813 33 Bratislava, Slovakia
Account number: 6624439050 / 1111
SWIFT code: UNCRSKBX
IBAN code: SK61 1111 0000 0066 2443 5050
The name of the recipient: TJUPA s.r.o.
When setting the payment, please in the information for the recipient, indicate:
name, surname and country of the participant
INSTRUCTIONS FOR LECTURERS

Presentations must be delivered on a removable device (cd, dvd, usb stick or external hdd) either in Adobe PDF or Microsoft Powerpoint version 2013 or lower format. If there are any videos attached to your presentation please place these videos in a separate folder together with your presentation file. We support two aspect ratios 4:3 and 16:9. In case your abstract does not fulfill these requirements please contact the organizer under union2016@tajpan.com at least 2 weeks prior the event.

SLIDEROOM

Please keep in mind you have to visit the slideroom to submit your abstract at least 2 hours prior to your presentation. In order to avoid queue in slideroom we advise you, if possible, to submit your presentations on 22. 6. between 13.00 and 16.00.

POSTERS

Dimension: 90 cm width / 110 cm height
Please leave your poster at the registration desk

CONFERENCE BADGE

Each registered participant will receive conference registration with the official label entitling him to enter. Participants who do not have this labels will not be able to participate in the conference.

OFFICIAL LANGUAGES

English, Russian

Interpretation will be provided in the main lecture hall

PARKING

Behind the building of the Slovak National Theatre

INTERNET ACCESS

WIFI – Secured only for the needs of Speakers in the hall

CERTIFICATES

The certificates will be provided at the end of the conference
22. 6. 2016 .............................................. 6 credits
23. 6. 2016 .............................................. 8 credits
24. 6. 2016 .............................................. 8 credits

INFORMATION FOR EXHIBITORS

Installation: 22. 6. 2016 from 00:30 until 06:00
removal: 24. 6. 2016 from 18:00 until 23:00
more information about exhibition space - jozef.nano@tajpan.com
Join The Union

Union members make up a powerful international network across more than 140 countries, working together to transform public health and provide health solutions for the poor.

Help shape the future of lung health by joining The Union.

BENEFITS

- Benefit from a worldwide network, active in over 140 countries
- Share knowledge and expertise with colleagues
- Link up with an international network of members through the online Members Directory
- Stay up to date with the latest policy and research
- Gain unique regional insight into issues faced on the ground – and be involved in finding solutions
- Access a collection of dedicated resources and materials put together by experts
- Take advantage of professional opportunities and training
- Participate in Union conferences at a discounted rate

Union members make up a powerful international network across more than 140 countries, working together to transform public health and provide health solutions for the poor.

Help shape the future of lung health by joining The Union.

I am always inspired by knowing that each day, as I do my research, care for my patients and teach my students, other Union members committed to the same mission are at work around the world.

Dr E. Jane Carter
President
International Union Against TB and Lung Disease

JOIN THE UNION
Find out more at theunion.org
@TheUnion_TBLH
facebook.com/TheUnionLungHealth
The list of posters

Tuberculosis I

P1/1. An isolated tuberculous adrenal mass with adrenal insufficiency: a rare presentation
Gyan Bharti, Praveen Pandey, Nitin Rathi (India)

P1/2. Cost implication and coping way of tuberculosis patients, and associated factors under directly observed tuberculosis treatment strategy in Addis Ababa, Ethiopia
Getahun B., Wubie M., Dejen G. (Ethiopia)

P1/3. Drug users among the tuberculosis patients in the republic of Macedonia
Zakoska M., Ilievska Poposka B., Popovska A. (Macedonia)

P1/4. Need of counselling to provide universal access to quality diagnostics and treatment services for all presumptive TB patients
Sinha N. (India)

P1/5. Optimal follow up duration among adult TB contacts – a population–based cohort study in TB endemic area
Jia–Yih Feng, San–Chi Chen, Cha–Jen Liu, Wei–Jun Su (Taiwan)

P1/6. Results of infection control implementation in TB facilities in Ukraine
Zaiko N., Volitsky J., Pavlova O., Gamarizina K. (Ukraine)

P1/7. The psychosocial context of tuberculosis treatment in urban settings of Tomsk: a qualitative interview
Sidorenko N. Y., Fedotkina T. Y., Krouk E. A. (Russia)

P1/8. Tuberculosis in Institutions for patients with mental disorder in Macedonia
Zakoska M., Ilievka Poposka B., Mitrevski V. (Macedonia)

P1/9. Factors associated with “loss to follow up” in new and previously treated TB patients in Tashkent, Uzbekistan
Gadoev J., Asadov D., Gazzal O. (Uzbekistan)

Mehmeti R. (Kosovo)

P1/11. Tool to monitor timely tuberculosis prevalence and incidence in a specific group of asylum seekers in the Netherlands
Schimmel H., Eriksens C., Slump E., de Vries G. (Netherlands)

P1/12. Novel graphic presentation of the epidemiology of tuberculosis
de Vries G., Eriksens C., van Hunen R., Schimmel H., van Soolingen (Netherlands)

P1/13. TB epidemiology in Romania in the last 10 years, from data collection to analysis of the impact indicators
Chioran D.I., Popescu G.G., Spanu V., Cianan N., Data–base Adm. Dragos Constant (Romania)

Dias A., Monteiro F., Gerós S., Silva J., Diamantino H., Duarte R. (Portugal)

Dzuracká A., Milíková M., Ferenc P., Strachan T., Fábiy J. (Slovakia)
The list of posters

P1/16. Evaluation of reliability and interobserver agreement in chest specialists in the TB-prevention in lower Austria
Hirtl T., Schauer U. (Austria)

Batinčič M., Grm Zupan S., Kern L., Požek L., Gorenšek M., Žolnir-Dovč M., Svetina P. (Slovenia)

P1/18. Social determinants for tuberculosis in Italians according to age: a different old story Italy 2013–2015

P1/19. Austria’s tuberculosis law
Hirtl T. (Austria)

P1/20. Current epidemiological situation of tuberculosis in Slovakia
Rams R., Solovič I., Švecová, J., Hudečková H., Švihrová V., Samihý M. (Slovakia)

P1/21. The Lady Windermere Syndrome
Matula B., Zajacová H., Košturiaková G., Kočalková A., Lievajová V., Levická N., Solovič I. (Slovakia)

P2/1. Depression as a frequent consequence of treatment immobilization in patients with Spondylitis tuberculosis
Harvanová I. (Slovakia)

P2/2. Effectiveness of preventive therapy of latent tuberculosis infection in children
N. Korneva, A. Starshinova, S. Ananiev, J. Ovchinnikova, I. Dovgaliuk (Russia)

P2/3. Nursing management of patients with tuberculosis
Kober L., Čopiaková M., Siska V. (Slovakia)

P2/4. Satisfying the bio-psycho-social and spiritual needs of the patient with Spondylitis tuberculosis during hospitalization
Harvanová I. (Slovakia)

P2/5. Stigmatization as one of the emotional problems of patients with tuberculosis
Kober L., Hadidomová M., Kovalčíková K. (Slovakia)

P2/6. Tuberculosis and marginalized groups – Medical and Nursing problem
Kober L., Čopiaková M. (Slovakia)

P2/7. Factsheet: Advice about contraception to female tb patients
O.L.G. van de Waarsenburg, A.M.M. Borkus-Dieks, C.G.M. Erkens, M. Verhagen (Netherlands)

Jenkins H. E. (USA)
<table>
<thead>
<tr>
<th>Posters (P2)</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P2/9</td>
<td>Tuberculosis in Pregnancy: A Review in Indian context</td>
<td>Tripathi P (India)</td>
</tr>
<tr>
<td>P2/10</td>
<td>Comparison of the effectiveness of therapy of pulmonary tuberculosis in children from contact with MDR-TB</td>
<td>Starshinova A., Ananev S., Korneva N., Ovchinnikova J., Dovgaliuk I. (Russia)</td>
</tr>
<tr>
<td>P2/11</td>
<td>Detection of latent tuberculosis infection in children with different results of tuberculin skin test</td>
<td>Korneva N., Ovchinnikova J., Dovgaliuk I., Starshinova A. (Russia)</td>
</tr>
<tr>
<td>P2/12</td>
<td>The effectiveness of therapy of latent tuberculosis infection in children</td>
<td>Starshinova A., Ananev S., Korneva N., Ovchinnikova J., Dovgaliuk I. (Russia)</td>
</tr>
<tr>
<td>P2/13</td>
<td>Knowledge of Tuberculosis by social workers included in the support of TB patients</td>
<td>Popovska A., Zakska M. (Macedonia)</td>
</tr>
<tr>
<td>P2/14</td>
<td>Complications after BCG vaccination</td>
<td>Milskova M., Melter J., Dzuracka A., Ostro R., Fabry J. (Slovakia)</td>
</tr>
<tr>
<td>P2/15</td>
<td>TB without borders</td>
<td>Dzuracka A., Milskova M., Ferenc P., Strachan T., Fabry J. (Slovakia)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Posters (P3)</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3/1</td>
<td>Financial expenses associated with poor treatment outcomes in the management of multidrug-resistant tuberculosis (MDR-TB) in Tomsk, Russia</td>
<td>I.Y.Gelmanova, N. A. Zemlyanaya, E. A. Krouk, A. B. Yedilbayev (Russia)</td>
</tr>
<tr>
<td>P3/2</td>
<td>New antituberculosis drug of thioacetazone group - tioureidoiminomethylpyridinium perchlorate in the clinical study</td>
<td>I. Chernokhaeva, M. Pavlova, A. Starshinova, N. Sapozhnikova, L. Archakova, E. Believa, P. Yablonskii. (Russia)</td>
</tr>
<tr>
<td>P3/5</td>
<td>Association of Interleukin-2 gene polymorphisms in patients with patients on multi-drug resistant tuberculosis</td>
<td>Butov D. O., Kuzhko M. M., Butova T. S., Piritatska N. E. (Ukraine)</td>
</tr>
<tr>
<td>P3/6</td>
<td>Design and synthesis of nanocarrier delivery systems (NDSs) for anti-tubercular drugs (ATDs)</td>
<td>Shivang K. Desai, Smritilekha Bera, Man Singh, Dhananjay Mondal (India)</td>
</tr>
</tbody>
</table>

**TB Treatment**

Chairmen: G. Groenen, I. Porvaznik

<table>
<thead>
<tr>
<th>Posters (P3)</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3/7</td>
<td>Влияние медико-социального сопровождения на эффективность лечения больных мультирезистентным туберкулезом в Украине</td>
<td>Масюк Л. А., Кузин И. В., Масюк О. И. (Ukraine)</td>
</tr>
</tbody>
</table>
Groenen G., Wamzin M., Arrazola de Oñate W. (Belgium)

P3/9. Clinical experience of inhaled nebulized antimycobacterial therapy in patients of first-diagnosed TB with concomitant tuberculosis of trachea and bronchi
Kuzhko M., Butov D., Avramchuk O.,Hulchuk N., Protsyk L.,Tlustova T. (Ukraine)

P3/10. Phase 2 trial of intravenous chemotherapy adjunct therapy in patients with destructive pulmonary TB
Kuzhko M., Butov D., Avramchuk O., Hulchuk N., Protsyk L.,Tlustova T. (Ukraine)

P3/11. Study of M. tuberculosis resistance to antitubercular drugs in some Kosovo regions (Prishtina, Ferizaj and Gjilan) during 2003-2014
Mehmeti R. (Kosovo)

P3/12. The use of bedaquiline for the treatment of lung tuberculosis with extensive drug resistant micobacterium: an Armenian experience
Nikolayan L., Hayrapetyan A., Manukyan A., Babayan T. (Armenia)

P3/13. Resistance to anti-tuberculotics - correlation of laboratory and clinical parameters
Porvaznik I., Moravčík J.,Bedő R., Solovič I. (Slovakia)

P4/1. Comparison of QuantiFERON®-TB Gold and Diaskintest® in children with latent TB infection and different results of tuberculin skin test
Korneva N., Ananiev S., Starshinova A., Ovchinnikova J.,Dovgaliuk I. (Russia)

P4/2. TB-HIV coinfection in the regions of the CTRI supervision
Yakimova M. (Russia)

P4/3. Integrated tuberculosis and HIV care in Ukraine: association of early ART with decreased mortality rate among people co-infected with TB and HIV.
N. Zakha, V. Pecherytsya, O. Danilenko, M. Deykun, O. Pavlova, K. Gamazina (Ukraine)

P4/4. Results of QuantiFERON®-TB Gold and TB.SPOT tests among patients with TB and HIV infection in the presence of different level of immuno-suppression
Manina V., Starshinova A., Parantea L., Zhuravlev V.,Pavlova M., Yakobinski P. (Russia)

P4/5. Role of Facility Integrated Counselling and Testing Centres (FICTC) in Bihar for strengthening of HIV-TB Co-ordination
Sinha N. (India)

P4/6. Assessment the importance of QuantiFERON®-TB Gold In-Tube test in diagnosis of active tuberculosis
Klimentová Z., Solovič I. (Slovakia)

P4/7. Impact of HIV infection on treatment outcome of tuberculosis in Europe
Karo B., Krause-G., Holte V., Van Der Werf M. J., Castel S., Hamsuda G., Haas W. (Germany)

Zaninov E.,Kozakova, D., Rybar I.,Rovensky J. (Slovakia)

P4/9. IGRA tests yesterday and now
Polarová M. (Slovakia)
<table>
<thead>
<tr>
<th>Poster Number</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>P5/1</td>
<td>Barriers in adoption of improved stoves: Inquiry among users, non-users and program managers in Sindh and Punjab provinces in Pakistan</td>
<td>Jamali T., Shahid A., Khoso A., Fatmi Z., Masood Kadir M., Sathiakumar N. (Pakistan)</td>
</tr>
<tr>
<td>P5/2</td>
<td>Short term impact of stoves in reducing household air pollution and improving health among rural women: comparison of two programs</td>
<td>Jamali T., Fatmi Z., Shahid A., Khoso A., Masood Kadir M., Sathiakumar N. (Pakistan)</td>
</tr>
<tr>
<td>P5/3</td>
<td>Validation of the ATS (American thoracic society) respiratory questionnaire for lung function assessment among an occupational group of textile workers</td>
<td>Jamali T., Nafees A. A. (Pakistan)</td>
</tr>
<tr>
<td>P5/4</td>
<td>The role of nitric oxide, reactive nitrogen and oxygen species in lung cancer</td>
<td>Bencova A., Antosova M., Kocan I., Miska D., Mikloko P., Rozborilova E. (Slovakia)</td>
</tr>
<tr>
<td>P5/5</td>
<td>Bone sarcoidosis in children – case report</td>
<td>Ferenc P., Mulska M., Holecky R., Strmiska F., Starchan T., Fabry J (Slovakia)</td>
</tr>
<tr>
<td>P5/6</td>
<td>Cryptogenic organising pneumonia</td>
<td>Slivka R., Janik P., Holecky R. (Slovakia)</td>
</tr>
<tr>
<td>P5/7</td>
<td>Determinants of subclinical atherosclerosis in patients with obstructive sleep apnoea</td>
<td>Trojova I., Kozarova M., Petranova D., Parancova I., Malachovska Z., Tjock I., Joppa P., Pobeha P., Thavova R. (Slovakia)</td>
</tr>
<tr>
<td>PS/9</td>
<td>The determination of specific Immunoglobulin G in relation to hypersensitivity pneumonitis in children</td>
<td>Strachan T., Meiter J., Ferenc P., Strmiska F., Mikloko M., Fabry J. (Slovakia)</td>
</tr>
<tr>
<td>PS/10</td>
<td>Tracheoesophageal fistula in 3-year old boy - case report</td>
<td>Ferenc P., Murgaš D., Strmiska F., Starchan T., Holecky R., Mikloko M., Mikulicik P., Fabry J. (Slovakia)</td>
</tr>
<tr>
<td>PS/11</td>
<td>Transthoracic needle biopsy under ultrasound guide</td>
<td>Slivka R., Javorská B., Hvizdová K., Rešteiová K., Janik P., Mikulčiaková A. (Slovakia)</td>
</tr>
<tr>
<td>PS/12</td>
<td>Serious course of miliary tuberculosis in COPD patient</td>
<td>Levická N., Lievajová V., Kočalková A., Dudašová J. (Slovakia)</td>
</tr>
</tbody>
</table>
**THE LIST OF POSTERS**

**PLÚČNE ZDRAVIE**
Preedsedajúci: A. Lesňáková, M. Bučeková

P6/1. Chylothorax stále prekvapuje
Bučeková M., Piovarči D., Nečesaná M. (Slovensko)

P6/2. Sarkolízis pleury
Kukoľ P., Jonner I., Urban J., Černá E.T., Janík P., Mikuľáková A. (Slovensko)

P6/3. Endogenous breathing in health promotion
Hudáková Z., Srpoňová M., Kutis P., Butorová A. (Slovensko)

P6/4. Copingové stratégie u pacientov s respiráciou
Mohnyánszki F. (Slovensko)

P6/5. Genotyping of MDRI Mycobacterium tuberculosis strains. Genotypizácia multirezistentných kmeňov
Melter J., Melterová K., Miškovská M., Strmiska F., Poľanová M., Solovič I., Fábry J. (Slovensko)

P6/6. Home mechanical ventilation from the viewpoint of nursing
Novysedláková M., Zrubáková K. (Slovensko)

P6/7. Is tuberculosis still a public health problem in Slovakia?
Šimor L. (Slovensko)

P6/8. Je gravidita zatažujúcim faktorom pri tuberkulóze?
Saade A., Solovič I., Budarišláková Y., Nevická E., Frečerová J. (Slovensko)

P6/9. Mendelian susceptibility to mycobacterial diseases caused by deletion 523delT
Melter J., Melterová K., Miškovská M., Strmiska F., Poľanová M., Solovič I., Fábry J. (Slovensko)

P6/10. Tuberkulóza a gravidita
Bučeková V. (Slovensko)

P6/11. Aj empyému hrudníka môže prekvapit
Bučeková V. (Slovensko)

P6/12. Nozaj pneumonía?
Černá E.T., Urban J., Jonner I. (Slovensko)

Tedlova E., Suchankova M., Durmanova V., Tiberinska E., Majer I., Novosadova H., Demian J., Bucova M. (Slovensko)

P6/14. Obrovský solitárny fibrózny tumor pleury
Tkačíková M., Puškárová K., Havelka V., Mikuľáková A. (Slovensko)

P6/15. Our experience with the Basophil activation test in the diagnosis of inhalant and food allergies with
BassoFlowEX kit
Kunč P., Bítvanská K., Melter J., Fábry J., Ferenc P. (Slovensko)
P6/16. Pepsin detection in saliva samples as a marker of extraesophageal reflux in children
Strachan T., Melter J., Ferenc P., Barabasová A., Fábry J. (Slovakia)

P6/17. Positive airway pressure therapy in patients with overlap syndrome
Hajduková A., Pobeha P., Kuklišová Z., Tiško R., Štrbová Z., Hašková R. (Slovakia)

P6/18. Risk groups for tuberculosis in Slovakia?
Samohýl M. (Slovakia)

P6/19. Sunshine vitamin
Betulová J., Ferenc P., Strachan T., Fábry J. (Slovakia)

Košturiaková G., Solovič I. (Slovakia)

Littva V., Andrasi I., Králová A. (Slovakia)

Krištúfková Z., Avdičová M., Štefkovičová M., Hudečková H., Bražinová A. (Slovakia)

P6/23. Ventilator-associated pneumonia rates in the intensive care unit of Central Military Hospital-University Hospital in Ružomberok, Slovakia
Hlinková S., Lesnáková A., Moraucíková E. (Slovakia)

P6/24. Biological Treatment of Ulcerative Colitis Complicated by Activation of Latent Tuberculosis Infection
Lesňáková, A., Littva V., Solovič I., Hlinková S. (Slovakia)

P6/25. Sarcoid-like granulomatóza u pacientov liečených antagonistami TNF-alfa
Urban J., Černá E.T., Jonner L., Mikuľaková A. (Slovakia)

P6/26. Study of drug resistance mechanisms in primary lung cancer
Muri J., Rybašová S. (Slovakia)

P6/27. Unilateral combination of lung carcinoma with absence of pulmonal artery
Pascherka A. (Slovakia)

P6/28. Videomediastinoscopy and EBUS in diagnosis of lung diseases
Garchár A., Muri J. (Slovakia)

P6/29. Pulmonary Rehabilitation in the Sanatorium Tatranska Kotlina
Oravec P. (Slovakia)

P6/30. Interakcie antituberkulotík
Dobáková, P., Goboova, M., Říky, J. (Slovakia)

P6/31. Donation of human organs, rule of law and acceptance in Slovakia
Anton Lisnik (Slovakia)
INDEX – REGISTER

LECTURES
Abduliev T. 97
Abubakar I. 44, 47
Ahamed N. 121
Ahmedov S. 9
Akhalaia M. 83
Alexandru S. 8
Andrasiova M. 69
Annesi-Maesano I. 116
Arnold G. 51
Avetisian A.I. 80
Bao J. 56
Barbova A.I. 134
Bhotamley G. 100
Black A. 43
Block N. 89, 92
Bobokhodjaev O. 87
Bogorodskaya E. 78
Borisov S. 79
Brezina M. 35
Brostrom R. 54
Cantau N. 98
Celan C. 18
Cirillo D.M. 103
Codlin A. 49
Dadu A. 49
Dagan S. 120
de Colombani P. 146
de Vries G. 28, 123
Dedicoat M. 20
Denisov A.I. 136
Deriu L. 93
Dravniece G. 15, 126, 128
du Clos P. 14
Duarte R. 108
Erkens C. 29
Falcon D. 52, 106
Fiasig L. 125, 147
Filipov A. 79
Fitting J.W. 117
Flo R. 37
Gamarra N. 17, 129
Gebhard A. 127
Girardi E. 27
Gonzalezova E. 141
Graziella M. 11
Gunner G. 102
Hadzavova S. 68
Hajkova M. 65, 140
Hayrapetyan A. 6
Hoffman H. 40
Hollander E. 38
Chemyanya E. 81
Chumsky J. 138
Idrisova M. 88, 90
Ismoina E. 82
Ivanov D. 79
Ivanushkina T. 79
Jansen N. 31
Jaramillo E. 15, 109, 119
Jenska H. 58
Jing Bao 56
Khechinashvili G. 95
Koilambelota G. 85
Kawko D. 64
Keane J. 23
Kocova E. 62
Kolev V. 33
Kralatsev K. 53
Kudiatshao G. 80
Kuklisova Z. 76
Lange Ch. 42, 105, 107
Lassan S. 72, 74, 139
Ley E. 45
Lin Y. 57
Livitvino N.A. 135
Livitvino N.A. 79
Makhmudova M. 129
Marina V. 82
Martina G. 80
Matteeli A. 26, 145
Matsa I. 67
Migliorini G.B. 24
Mirzade B. 129
Mirzaev F. 83
Mirzaeva F. 19
Mozor Z. 149
Muhamin A. 81
Mustakautio D.E. 53
Niemann S. 122
On Min K. 21
Panteveev A. 82
Papay P. 143
Papirnia N. 5, 86
Pavlova M. 82
Pavlova O. 91
Reichman L. 118
Rigouts L. 39
Ritz N. 73
Romancenco E. 82
Ruhwald M. 32
Sester M. 101
Sismanidis B. 10
Sominova I. 82
Sotgiu G. 25
Sprynytsan T. 136
Stagg H. 99
Starka A. 41
Starshina A. 82
Stary A. 48
Sulamanova M. 91
Terievka I. 4
Thomas J. 124
Tillyashylyev M. 5
Tlakova R. 66, 70, 75, 77
Turkova A. 12
v Leth F. 104
Valpuri A. 71
v van den Boom M. 94
v van den Hof S. 130
v van den Molen T. 73
v van Hunen R. 32
v van Rest J. 30
v Vasilieva E. 82
v Vasiliev I. 80
v Vasiliev I. 2
v Vasakova M. 61
v Votyagov S. 99
v Vyasova A. 81
v Vyshegradsky R. 63
v Walker T. 42
v Woltmann G. 22
v Yablonskiy P. 80

INDEX – REGISTER
<table>
<thead>
<tr>
<th>Name</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poľanová M. P6/13.</td>
<td></td>
</tr>
<tr>
<td>Ratnič K. P1/1.</td>
<td></td>
</tr>
<tr>
<td>Ramas R. P1/20.</td>
<td></td>
</tr>
<tr>
<td>Roztočilová E. P5/6.</td>
<td></td>
</tr>
<tr>
<td>Samoň M. P5/1, P6/18.</td>
<td></td>
</tr>
<tr>
<td>Szapalkovszky N. P3/2.</td>
<td></td>
</tr>
<tr>
<td>Shahid A. P5/1, P5/2.</td>
<td></td>
</tr>
<tr>
<td>Schauz U. P1/16.</td>
<td></td>
</tr>
<tr>
<td>Schrems H. P1/11., P1/12.</td>
<td></td>
</tr>
<tr>
<td>Sidorenko N. Y. P1/7.</td>
<td></td>
</tr>
<tr>
<td>Sinha N. P1/4, P6/5.</td>
<td></td>
</tr>
<tr>
<td>Slump E. P1/11.</td>
<td></td>
</tr>
<tr>
<td>Srpová M. P6/3.</td>
<td></td>
</tr>
<tr>
<td>Staršinová A. P2/2, P2/10, P2/11, P2/12, P3/2, P4/1, P4/4.</td>
<td></td>
</tr>
<tr>
<td>Su W. J. P1/5.</td>
<td></td>
</tr>
<tr>
<td>Suchanová M. P6/13.</td>
<td></td>
</tr>
<tr>
<td>Števčíková M. P6/12.</td>
<td></td>
</tr>
<tr>
<td>Tadolini M. P1/18, P1/19.</td>
<td></td>
</tr>
<tr>
<td>Tedlova E. P6/13.</td>
<td></td>
</tr>
<tr>
<td>Tibenská E. P6/10.</td>
<td></td>
</tr>
<tr>
<td>Tklíč V. P6/17.</td>
<td></td>
</tr>
<tr>
<td>Tučáková M. P6/14.</td>
<td></td>
</tr>
<tr>
<td>von de Woestenbergh G. L. G. P2/7.</td>
<td></td>
</tr>
<tr>
<td>von der Werf M. J. P4/7.</td>
<td></td>
</tr>
<tr>
<td>von Hunen R. P1/12.</td>
<td></td>
</tr>
<tr>
<td>von Sosteen D. P1/3.</td>
<td></td>
</tr>
<tr>
<td>Verhagen M. P2/7.</td>
<td></td>
</tr>
<tr>
<td>Volskyi J. P1/6.</td>
<td></td>
</tr>
<tr>
<td>Wubke M. P1/2.</td>
<td></td>
</tr>
<tr>
<td>Yalnikova M. P4/2.</td>
<td></td>
</tr>
<tr>
<td>Yedidtayev A. B. P4/1.</td>
<td></td>
</tr>
<tr>
<td>Zajacová H. P1/21.</td>
<td></td>
</tr>
<tr>
<td>Zakoska M. P1/3, P1/8.</td>
<td></td>
</tr>
<tr>
<td>Zakoska M. P2/13.</td>
<td></td>
</tr>
<tr>
<td>Zelënyanová N. A. P3/1.</td>
<td></td>
</tr>
<tr>
<td>Žolnir-Dovč M. P1/17.</td>
<td></td>
</tr>
<tr>
<td>Hyzen H. B. P3/7.</td>
<td></td>
</tr>
</tbody>
</table>

THANK YOU FOR YOUR PARTICIPATION IN THE CONFERENCE AND YOUR VISIT TO BRATISLAVA – THE CAPITAL OF SLOVAKIA.
VRÁŤTE SA K CHVÍLAM, NA KTORÝCH ZÁLEŽÍ

- Fixná kombinácia LAMA/LABA s 24 - HODINOVOU KONTROLOU SYMPTÓMOV CHOCHP*
- s dávkovaním 2 X DENNE1
- dvojroková aplikácia1

Aclidinium bromid/ Formoterol fumarát

SmPC Duaklir® GENUAIR®

* v porovnani s monoterapiami

1. Duaklir® Genuair®, Súhrn charakteristických vlastností lieku, dátum poslednej revízie Máj 2015

PDUA0019SK092015
**ADVAGRAF**

**Takrolimus s predĺženým uvoľňovaním**

**Odporúčané dávky – liečba rejekcie: transplantácia obličiek a pečene:**

Tento prevod vykonaný v pomere 1 : 1 (mg : mg) celkovej dennej dávky.

Dvakrát denne a vyžadujú prevod na Advagraf raz denne, by mal byť
ktorí sú na udržiavacej terapii prípravkom Prograf tobolky podávaným
inými imunosupresívnymi liečivými prípravkami u dospelých pacientov.

**Liečba v prípade odlučovania aloimplantátu nereagujúceho na liečbu**

U pacientov príjemcov alotransplantátu,
prípravkom Prograf na Advagraf:

prípravkom Advagraf.

**Dávkovanie a spôsob podania:**
Užíva sa nalačno, aby sa tak dosiahla maximálna absorpcia.

Advagraf je perorálna forma takrolimu určená na podávanie raz denne.

**Kontraindikácie:**

Hypersenzitivita na takrolimus alebo iné makrolidy alebo na

**Indikácie:**

Profylaxia rejekcie transplantátu

**Dávkovanie:**

Inštrukcie pro useknutie:Astellas Pharma Europe B.V.; Elisabethhof 19, 2353 Leiderdorp, Holandsko.

Registračné číslo:

EÚ/1/07/387/001, EÚ/1/07/387/002, EÚ/1/07/387/003, EÚ/1/07/387/004, EÚ/1/07/387/005,
EÚ/1/07/387/006; Advagraf 3 mg: EÚ/1/07/387/011, EÚ/1/07/387/012,
EÚ/1/07/387/013; Advagraf 5 mg: EÚ/1/07/387/007, EÚ/1/07/387/008,
EÚ/1/07/387/009; V tejto časti sa, prosím, oboznámte s úplným znením Súhrnu informácií
zdravotného poistenia.

Zdravotnícka dozorčia: v prípade potrebou konzultácie, obráťte sa na žiadnu z držiteľov príslušného zdravotníckeho dozorčia, s ktorým bol byť prípadný výsledok

Uchovávajte
Držiteľ rozhodnutia o registrácii:

**Slovak NatioNal theatre • Bratislava, Slovakia • 22 - 24 June 2016**

7th conference of the UnIon eUroPe regIon

**Slovak NatioNal theatre • Bratislava, Slovakia • 22 - 24 June 2016**

**7th conference of the UnIon eUroPe regIon**
**Novinka** Od 1.4.2016

---

**Pevné základy pokroku v manažmente CHOCHP**

- Významné zlepšenie púvodných funkcií hned od začiatku udržiavacej liečby
- Významné zlepšenie symptómov CHOCHP
- Lepšia kvalita života pre väčšiu počet pacientov

**SPIOLOTO® Výsledok viditeľný hned od začiatku udržiavavej terapie CHOCHP**

---

**SKRÁTENÁ INFORMÁCIA O LIEKU**

**Názov lieku:** Spiolto Respimat 2,5 mikrogramu/2,5 mikrogramu, inhalačný roztok.

**Zloženie lieku:** Podaná dávka je 2,5 mikrogramu tiotropia a 2,5 mikrogramu olodaterolu na jeden vstrek. Dva vstreky je jedna liečebná dávka.

**Indikácie:** Bronchodilatans na udržiavavú liečbu na zmiernenie príznakov u dozadostých pacientov s chronickou obštrukčnou chorobou płuć (CHOCHP).

**Dávkovanie a spôsob podávania:** Odporúčaná dávka pre dospelých je 5 mikrogramov tiotropia a 5 mikrogramov olodaterolu podaná v dvoch vstrekoch z inhalátora Respimat jedenkrát denne, vždy v rovnakom čase.

**Kontraindikácie:** Precitlivenosť na tiotropium, olodaterol alebo na ktorúkoľvek z pomocných látok. Precitlivenosť na atropín alebo jeho deriváty, napríklad ipratropium alebo oxitropium, v anamnéze.

**Špeciálne upozornenia:** Nemá sa používať pri astme. Nie je indikovaný na liečbu akútnych záchvatov bronchospazmu. Môže viesť k paradoxnému bronchospazmu. U pacientov s glaukom so zatvoreným uholom, hyperpláziou prostaty alebo ak na vlastníkach uholom sa vyskytuje fyzická zátlačená manéva. Sucho v ústach môže pri dlhodobom používaní viesť k zubnému kazu. U pacientov s poruchami srdca a srdcovnej činnosti sa má liek podávať s opatrnosťou. U niektorých pacientov je možná hypokaliémia.

**Liekové a iné interakcie:** Spiolto Respimat sa používa súbežne s inými liekmi na CHOCHP vrátane krátkodobo pôsobiacich sympatomimetických bronchodilatácií a inhalačných kortikosteroidov bez klinických dôkazov liekových interakcií.

**Gravidita a laktácia:** O používaní u tehotných žien je veľmi obmedzené množstvo údajov. Nežiaduce účinky:

**Časté:** sucho v ústach. **Menej časté:** závraty, bolesti hlavy, insomnia, atrialná fibrilácia, supraventrikulárna tachykaridia, tachykardia, hypertenzia, kašeľ, zápcha. **Spôsob uchovávania:** Nie je používaný v mrazničke. **Držiteľ rozhodnutia o registrácii:** Boehringer Ingelheim International GmbH, Ingelheim nad Rýnom, Nemecko. **Dátum revízie:** Jún 2015.

ANORO ELLIPTA, udržiavacia bronchodilatačná liečba pre pacientov s CHOCHP, ktorí trpia dýchavou.

ANORO ELLIPTA POSKYTUJE OKAMŽITÉ VÝSLEDKY, KTORÉ PACIENTI MÔŽU POCÍTÍT IHNEĎ...1,2

dýchajte umeklidínium/vilanterol

ANORO ELLIPTA, údržiavací bronchodilatátor pre pacientov s CHOCHP, ktorí trpia dýchacou obštrukciou. Udržiavacia liečba pre pacientov s chronickou obštrukčnou chorobou pľúc (CHOCHP) je dôležitá pre zlepšenie kvality života pacientov a prevenciu závažných sporadických a frekventovanej dažďačají pacientov s chronickou obštrukčnou chorobou pľúc (CHOCHP).

ANORO ELLIPTA je uvedený na zoznamu liekov schválených za účely ochrany zdravia zdravotníctva v roku 2016. Tento liek je určený na udržiavací bronchodilatáciu pri znižovaní akutných sporadických a frekventovanej dažďačají pacientov s chronickou obštrukčnou chorobou pľúc (CHOCHP) a zlepšovanie ich kvality života.

Indikácie:
ANORO je indikovaný na udržiavaciu bronchodilatačnú liečbu na zmiernenie príznakov u dospelých pacientov s chronickou obštrukčnou chorobou pľúc (CHOCHP).

Dávkovanie:
Dospelí:
Odporúčaná dávka je jedna inhalácia ANORA 55 mikrogramov/22 mikrogramov jedenkrát denne. ANORO sa má podávať jedenkrát denne v rámci liečby CHOPCH. ANORO je určený len na inhalačné použitie. ANORO nesmie byť podávaný riahaní. ANORO nesmie byť podávaný pacientom s ťažkou poruchou funkcie pečene.

Spôsob podávania:
ANORO je určený len na inhalačné použitie. ANORO nesmie byť podávaný riahaní. ANORO nesmie byť podávaný pacientom s ťažkou poruchou funkcie pečene.

Kontraindikácie:
Precitlivenosť na liečivá alebo na ktorúkoľvek z pomocných látok. U pacientov s diabetom sa má po začatí liečby starostlivejšie sledovať hladina glukózy v plazme.

Osobitné upozornenia:
Umeklidínium/vilanterol sa nemá používať u pacientov s astmou, keďže sa u tejto skupiny pacientov nesledoval.

U pacientov s diabetom sa má po začatí liečby starostlivejšie sledovať hladina glukózy v plazme.

U pacientov s diabetom sa má po začatí liečby starostlivejšie sledovať hladina glukózy v plazme.

U pacientov s diabetom sa má po začatí liečby starostlivejšie sledovať hladina glukózy v plazme.

U pacientov s diabetom sa má po začatí liečby starostlivejšie sledovať hladina glukózy v plazme.

U pacientov s diabetom sa má po začatí liečby starostlivejšie sledovať hladina glukózy v plazme.

U pacientov s diabetom sa má po začatí liečby starostlivejšie sledovať hladina glukózy v plazme.

U pacientov s diabetom sa má po začatí liečby starostlivejšie sledovať hladina glukózy v plazme.

U pacientov s diabetom sa má po začatí liečby starostlivejšie sledovať hladina glukózy v plazme.

U pacientov s diabetom sa má po začatí liečby starostlivejšie sledovať hladina glukózy v plazme.
Beta2-adrenergné agonisty s dlhým účinkom môžu zvýšiť riziko závažných nežiaducich udalostí súvisiacich s astmou, vrátane úmrtí súvisiacich s astmou, keď sa používajú na liečbu astmy.

Pacientom s konvulzívnymi poruchami alebo tyreotoxikózou, ako i pacientom s neprimeranými reakciami na beta2-adrenergné agonisty, má podávať s opatrnosťou pacientom s kardiovaskulárnymi ochoreniami. V prípade výskytu takýchto účinkov môže byť potrebné liečbu ukončiť.

Ultibro® Breezhaler® sa nemá podávať súčasne s beta-adrenergnými blokátormi (vrátane očných kvapiek), pokiaľ na ich používanie nie je závažný dôvod.

Paradoxný bronchospazmus: V klinických skúšaniach lieku Ultibro® Breezhaler® sa nepozoroval paradoxný bronchospazmus. Avšak v prípade jeho výskytu sa má podávanie okamžite ukončiť a má sa začať dostupné údaje o použití lieku Ultibro® Breezhaler® u pacientov s ťažkou poruchou funkcie pečene.

Neočakáva sa klinicky závažná lieková interakcia pri súbežnom používaní glykopyrónia s cimetidínom alebo inými inhibítormi transportu organických katiónov.

Cimetidín alebo iné inhibítory transportu organických katiónov: Ultibro® Breezhaler® sa má používať opatrne u pacientov s glaukómom s úzkym uhlom a u pacientov s retenciou moču.

Úplný zoznam nežiaducich účinkov si pozrite v súhrne charakteristických vlastností lieku.

Poznámka:
EU/1/13/862/001-008
Výdaj lieku je viazaný na lekársky predpis. Pred predpísaním lieku si prečítajte súhrn charakteristických vlastností lieku, ktorý získate na uvedenej adrese:
Registračné čísla: 6, 10, 12, 30, 90, 96 a 150 kapsúl, inhalátor
Október 2015

Ultibro® Breezhaler® 85 mikrogramov/43 mikrogramov

萝沐® Breezhaler® 85µg/43µg

Salmeterol/flutikazón 500/50 mg BID.

Symposium organized and funded by Pfizer

Pneumococcal vaccination – one of the most successful public health measures

Friday June 24th, 11:15 – 12:00 a.m.

Chair: Assoc. Prof. Ivan Sadoší (Slovakia)

The impact of pneumococcal conjugated vaccines on public health
Prof. Ron Dagan (Israel)

There is an opportunity to meet the expert on the booth right after the Pfizer symposium.

Pfizer Vaccines team is looking forward to seeing you.
The most accurate test for TB infection

QuantiFERON®-TB Gold Plus (QFT®-Plus) provides the accuracy that clinicians demand with the convenience of a single patient visit.

QFT®Plus is an improved version of the market-leading IGRA, QuantiFERON®-TB Gold. The test uses the same principle, test procedures, and reliable technology, but it is now optimized with innovative tuberculosis-specific antigens that elicit both CD8+ and CD4+ T-cell responses — enabling a more accurate assessment of cell-mediated immune response to TB infection [1].

Meet us at our booth and ask us how QFT®Plus can help you simplify TB screening.

QuantiFERON-TB Gold Plus (QFT®Plus) is CE-marked for use in Europe.


Trademark: QIAGEN®, QFT®, QuantiFERON® (QIAGEN Group). © 2016 QIAGEN, all rights reserved.
7th CONFERENCE OF THE UNION EUROPE REGION

SLOVAK NATIONAL THEATRE

Bratislava, Slovakia

22 - 24 June 2016